Feb 19, 2021 8:00am EST Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Feb 17, 2021 7:47am EST Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
Feb 10, 2021 7:00am EST Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
Feb 08, 2021 8:05am EST Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies
Feb 03, 2021 8:00am EST Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Feb 01, 2021 7:30am EST Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
Jan 19, 2021 11:59am EST Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants
Jan 19, 2021 8:03am EST Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
Jan 11, 2021 8:00am EST Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment
